Chemo-Immunotherapy: A New Trend in Cancer Treatment
Clicks: 87
ID: 281766
2023
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
25.8
/100
87 views
25 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #64 of 68 articles by views in Cancers
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Simple Summary Chemoimmunotherapy is an emerging treatment option for cancer that combines traditional chemotherapy with immunotherapy. This approach aims to increase the efficacy of cancer treatment by simultaneously targeting cancer cells through chemotherapy and boosting the immune system’s ability to fight cancer through immunotherapy. Several studies have shown promising results after using chemoimmunotherapy to treat various types of cancer, including melanoma and lung cancer. However, the optimal dosing, timing, and sequencing of these treatments still require further investigation. In this review, we summarize recent advances and future directions in the field of chemoimmunotherapy in the clinical management of patients with cancer. Abstract Chemotherapy has been the basis of advanced cancer treatment for decades. This therapy has largely been considered immunosuppressive, yet accumulated preclinical and clinical evidence shows that certain chemotherapeutic drugs, under defined conditions, may stimulate antitumor immunity and potentiate immune checkpoint inhibitor (ICI)-based therapy. Its effectiveness has been highlighted by recent regulatory approvals of various combinations of chemotherapy with ICIs in several tumors, particularly in some difficult-to-treat cancers. This review discusses the immune modulatory properties of chemotherapy and how they may be harnessed to develop novel chemo-immunotherapy combinations. It also highlights the key determinants of the success of chemo-immunotherapy and provides an overview of the combined chemo-immunotherapies that have been clinically approved.
| Reference Key |
sordo-bahamonde2023chemoimmunotherapy
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Christian Sordo-Bahamonde; Seila Lorenzo-Herrero; A. Gonzalez-Rodriguez; Alejandra G Martinez-Perez; J. Rodrigo; J. García-Pedrero; S. González |
| Journal | Cancers |
| Year | 2023 |
| DOI |
10.3390/cancers15112912
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.